Intelligent Bio Solutions completes method comparison study for fingerprint drug screening system ahead of FDA 510(k) filing

• Intelligent Bio Solutions completed a multi-site method comparison clinical study for its Intelligent Fingerprinting Drug Screening System to support an FDA 510(k) filing for codeine detection.
• Results have not been presented yet; data analysis is underway with independent laboratory confirmation, ahead of inclusion in the FDA submission package.
• The study met its operational aim by showing typical workplace screening staff can use the system accurately in real-world screening settings.
• The company now shifts to final analysis and submission assembly, targeting an FDA 510(k) filing in the second half of 2026 to enter the U.S. market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110830PRIMZONEFULLFEED9806903) on August 11, 2026, and is solely responsible for the information contained therein.